FLT3 and acute myeloid leukemia: Similarly, 8 of 11 children with relapsed/refractory AML (5 FLT3-ITD and 3 FLT3-wild-type) treated on a Phase 1 trial at SJCRH with sorafenib, clofarabine, and cytarabine achieved CR or CR with incomplete blood count recovery (CRi) (76).